On 5 June 2026, Qyuns Therapeutics Co., Ltd. executed an on-market repurchase of 253,200 H-shares, paying a total of HK$3.83 million. The shares were repurchased at prices ranging from HK$14.64 to HK$15.80, with a volume-weighted average cost of HK$15.11 per share.

Following the transaction: • Issued shares (excluding treasury shares) decreased to 223.75 million from 224.00 million, a reduction of 0.11%. • Treasury shares rose to 3.32 million from 3.07 million, keeping total issued shares unchanged at 227.07 million.

Repurchase mandate status: • Authorised limit: 22.44 million shares. • Cumulative repurchases under the mandate: 616,600 shares, representing 0.27% of the company’s issued share capital on the mandate date (29 May 2026).

Under Hong Kong Listing Rules, Qyuns Therapeutics is restricted from issuing new shares or disposing of treasury shares until 5 July 2026. The company confirms that the buyback complied with all relevant Main Board requirements.